Authors : Pharm Sheka Sankoh; Pharm Abdulai Turay; Dr. Eugene BS Conteh

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/mvzh4jxk

Scribd : https://tinyurl.com/e3w85723

DOI : https://doi.org/10.38124/ijisrt/25jul454

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Background: Diabetes mellitus, particularly type 2 diabetes, is a multifactorial metabolic disorder often accompanied by dyslipidemia and oxidative stress-related organ damage. While synthetic antidiabetic agents offer glycemic control, their long-term use is associated with adverse effects. Polyherbal formulations present a promising alternative due to their multifaceted therapeutic properties and favorable safety profiles.  Objective: This study aimed to evaluate the antilipidemic, hypoglycemic, and organ-protective effects of a polyherbal formulation, RAXI, in a rat model of type 2 diabetes induced by high-fat diet (HFD) and streptozotocin (STZ).  Methods: Male Wistar rats were divided into normal, diabetic control, and treatment groups. Diabetes was induced using a high- fat diet followed by STZ injection. RAXI was administered orally at doses of 100, 200, and 400 mg/kg for 28 days. Glibenclamide (5 mg/kg) served as the standard drug. Parameters assessed included fasting blood glucose (FBG), lipid profile, renal function markers (urea and creatinine), and antioxidant enzymes (MDA, GSH, CAT, SOD, GST). Data were analyzed using two-way ANOVA with Tukey’s post hoc test.  Results: RAXI produced a dose-dependent reduction in fasting blood glucose, with the 400 mg/kg dose showing a significant decrease (p < 0.001) comparable to Glibenclamide. Lipid profile analysis revealed significant reductions in TG, TC, and LDL-C (p < 0.01–0.001) and increased HDL-C levels (p < 0.05–0.01). Renal markers (urea and creatinine) and oxidative stress indicators (MDA and GSH) were significantly improved (p < 0.01–0.001), alongside elevated catalase activity (p < 0.001). Body weight remained statistically unchanged across all groups (p = 0.8459), indicating metabolic neutrality of RAXI.  Conclusion: RAXI exhibits significant antidiabetic, antilipidemic, and nephroprotective effects, likely due to its antioxidative mechanisms. These findings support its traditional use and encourage further investigation as an integrative therapeutic for type 2 diabetes and associated complications.

Keywords : Polyherbal Formulation; RAXI; Diabetes Mellitus; Antioxidant Activity; High-Fat Diet; Streptozotocin; Lipid Profile; Glycated Hemoglobin; Renal Biomarkers; Oxidative Stress.

References :

1. Abdelaziz, T. H., Yassin, M. H., & El-Hadidy, W. (2020). Antidiabetic and antioxidant potential of some medicinal plants. Journal of Pharmacognosy and Phytochemistry, 9(4), 1204–1210.
2. American Diabetes Association. (2022). Standards of medical care in diabetes 2022. Diabetes Care, 45(Supplement_1), S1–S264. https://doi.org/10.2337/ dc22-S001
3. Gerich, J. E. (2010). Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications. Diabetic Medicine, 27(2), 136–142.
4. Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005). Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 28(1), 164–176.
5. Lusis, A. J., Pajukanta, P., & Davis, R. C. (2007). Genetic basis of dyslipidemia. Nature Reviews Genetics, 8(6), 492–501.
6. Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism, 5(3), 150–159.
7. Rani, V., Deep, G., Singh, R. K., Palle, K., & Yadav, U. C. S. (2016). Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sciences, 148, 183–193.
8. Rohilla, A., & Ali, S. (2012). T2DM and cardiovascular diseases: Antidiabetic potential of medicinal plants. Journal of Pharmacognosy and Phytochemistry, 1(2), 1–7.
9. Rohlfing, C. L., Wiedmeyer, H. M., Little, R. R., England, J. D., Tennill, A., & Goldstein, D. E. (2002). Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care, 25(2), 275–278.
10. Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., ... & Molitch, M. E. (2014). Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care, 37(10), 2864–2883.
11. Eddouks, M., Maghrani, M., Lemhadri, A., Ouahidi, M. L., & Jouad, H. (2012). Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the southeastern region of Morocco (Tafilalet). Journal of Ethnopharmacology, 82(2–3), 97–103. https://doi.org/10.1016/S0378-8741(02)00164-2
12. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Brussels, Belgium.

13. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. The Lancet, 383(9922), 1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6
14. Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., ... & Segal, J. B. (2016). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Annals of Internal Medicine, 164(11), 740–751. https://doi.org/10.7326/M15-2650
15. Patel, D. K., Prasad, S. K., Kumar, R., & Hemalatha, S. (2012). An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pacific Journal of Tropical Biomedicine, 2(4), 320–330. https://doi.org/10.1016/S2221-1691(12)60032-X
16. Prasad, S., & Sung, B. (2015). Oxidative stress and cancer: Chemopreventive and therapeutic role of polyphenols. In B. Aggarwal & S. Shishodia (Eds.), Molecular targets and therapeutic uses of spices (pp. 449–475). Springer.
17. Rizvi, S. I., & Mishra, M. (2013). Traditional Indian medicines used for the management of diabetes mellitus. Journal of Diabetes Research, 2013, 712092. https://doi.org/10.1155/2013/712092
18. Szkudelski, T., & Szkudelska, K. (2015). Anti-diabetic effects of resveratrol. Annals of the New York Academy of Sciences, 1348(1), 1–10. https://doi.org/10.1111/nyas.12894
19. Tiwari, A. K., & Rao, J. M. (2002). Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and prospects. Current Science, 83(1), 30–38.
20. Wilson M, Tan Y, Wang J, et al. Antidiabetic efficacy of a six-herb polyherbal formulation in STZ-induced diabetic rats. J Ethnopharmacol. 2023;308:116351.
21. Bhatt P, Manjunatha M, Thakurdesai P. Antidiabetic and antioxidant effects of Glyoherb in experimental type 2 diabetic rats. J Ayurveda Integr Med. 2021;12(3):456–463.
22. Haye SS, Khalid M, Husain A, et al. Polyherbal formulation activates AMPK–IRS–PI3K–Akt pathway and enhances antioxidant status in diabetic rats. Biomed Pharmacother. 2022;152:113255.
23. Rajani GP, Kumar P, Purnima A. A polyherbal formulation ameliorates hyperglycemia and oxidative stress in STZ-induced diabetic rats. Pharm Biol. 2022;60(1):52–60